August 25, 2026
Perseus Proteomics Inc.
President & CEO: Takuya Yokokawa
e-mail: ir@ppmx.com

Completion of the TOKYO Strategic Innovation Promotion Project

We are pleased to announce that our project, “Development of a Novel Functional Antibody Acquisition Platform Technology,” selected for the fiscal 2023 TOKYO Strategic Innovation Promotion Project of the Tokyo Metropolitan Small and Medium Enterprise Support Center, has been completed as planned and has passed the required final inspection.

Through this project, we established a novel antibody acquisition platform technology that enables the entire process—from selecting antibody-secreting cells to obtaining antibody gene sequence information—to be performed as an integrated workflow. This technology provides a foundation for streamlining the antibody-generation process, which has traditionally required considerable time and effort, and for rapidly obtaining a wide variety of functional antibodies.

Going forward, we will leverage this platform technology to expand our antibody research support services, strengthen sales of antibodies and reagents, and advance research and development aimed at creating new antibody drug candidates.

The impact of this project on our financial results for the current fiscal year is expected to be immaterial. We will continue to work toward enhancing our corporate value over the medium to long term through business development utilizing this platform technology.

Related Information
For more information about the TOKYO Strategic Innovation Promotion Project, please visit the following website:
https://www.tokyo-kosha.or.jp/support/josei/jigyo/tokyo-innovation.html